Using big data to generate actionable clinical intelligence in PAP treatment

Jean-Louis Pépin

Source: 5th Sleep and Breathing Conference
Number: 52

Slide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Jean-Louis Pépin. Using big data to generate actionable clinical intelligence in PAP treatment. 5th Sleep and Breathing Conference

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
New uses of data: from big data to artificial intelligence and clinical decision tools  in children with respiratory diseases
Source: Virtual Congress 2021 – New technologies for the management of children with respiratory diseases
Year: 2021

From clinical trials to real-world data: New dimensions of patient benefits
Source: International Congress 2015 – IgE-mediated asthma: New revelations and future insights
Year: 2015

Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough
Source: Eur Respir J 2015; 46: 607-614
Year: 2015

Pirfenidone: an update on clinical trial data and insights from everyday practice
Source: Eur Respir Rev 2014; 23: 111-117
Year: 2014

Do the current endpoints in IPF clinical trials allow good regulatory decisions to be made?
Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases"
Year: 2014

How to use monitoring data to make wise clinical decisions
Source: International Congress 2015 – PG3 Cardiorespiratory monitoring in critically ill patients
Year: 2015

Using big data to change healthcare: improving quality of care with routine data
Source: International Congress 2016 – Primary Care Day: challenging times III
Year: 2016

Large trials, new knowledge: the changing face of COPD management
Source: Eur Respir J 2015; 45: 1692-1703
Year: 2015

Establishment of an integrated clinical network and comprehensive data warehouse for the conduct of comparative effectiveness research in COPD
Source: Annual Congress 2011 - COPD: integrated care and rehabilitation
Year: 2011

How can real-world data be used to improve outcomes?
Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC
Year: 2021

Adding biological markers to COPD categorisation schemes: a way towards more personalised care?
Source: Eur Respir J 2016; 47:1601-1605
Year: 2016

Some principles and practices of genetic biobanking studies
Source: Eur Respir J 2009; 33: 419-425
Year: 2009

Is data quality more important than data quantity in the diagnosis of occupational asthma from serial PEF records?
Source: Annual Congress 2010 - Occupational and environmental exposures and respiratory disease
Year: 2010

A machine learning approach to suspect excessive inactivity in COPD patients using non-activity-related clinical data
Source: Virtual Congress 2021 – New approaches to pulmonary rehabilitation and chronic care
Year: 2021

There is no rationale to still rely on outdated, biased tools for quantitative morphology in pulmonary research
Source: Eur Respir Rev 2006; 15: 105-106
Year: 2006

Is there a need for ongoing support for the interpretation of spirometry results by general practitioners?
Source: Eur Respir J 2006; 28: Suppl. 50, 740s
Year: 2006

Revising our approach to conducting therapeutic clinical research in COPD
Source: Eur Respir J, 51 (2) 1702712; 10.1183/13993003.02712-2017
Year: 2018

What requirements should a biomarker meet to be used in the clinical and epidemiological setting?
Source: Annual Congress 2008 - Biomarkers in COPD - application in clinical and epidemiological studies
Year: 2008

The NIVO score: can it help to improve noninvasive ventilation in daily clinical practice?
Source: Eur Respir J, 58 (2) 2100336; 10.1183/13993003.00336-2021
Year: 2021